1 / 14

Cervical Cancer

Cervical Cancer. By:Marisela Esparza. Cervical Cancer is cancer in the cervix (the lower part of the cervix that connects to the vagina.) . Causes: Abnormal Change in tissue. Human Papillomavirus There are 80 types of HPV Transmitted Sexually Cause 90% of Cervical Cancer

DoraAna
Télécharger la présentation

Cervical Cancer

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Cervical Cancer By:Marisela Esparza

  2. Cervical Cancer is cancer in the cervix (the lower part of the cervix that connects to the vagina.)

  3. Causes: Abnormal Change in tissue • Human Papillomavirus • There are 80 types of HPV • Transmitted Sexually • Cause 90% of Cervical Cancer • Cause Genital Warts

  4. Symptoms • Unusual Vaginal Discharge • Bleeding or “spotting” outside of menstruation • Pain or vaginal bleeding during sexual intercourse • Post- menopausal bleeding • Pain during urination • Pelvic Pain

  5. Risk Factors • Unprotected Sex • Multiple Sex partners • Using Oral Contraceptives • Immunosuppression • Smoking • Chlamydia

  6. Treatment • Radiation • Surgery • Chemotherapy • New drugs still on clinical trials

  7. Prevention • Vaccines (Gradasil, Cervarix) • Protected Sex • Regular Pap Tests

  8. Scientific Article Human papilloma vaccines launch a era of cervical cancer prevention. This was a study to see which vaccine was better gardasil or ceravix

  9. Table 1: Characteristics of the HPV vaccines Gardasil and Cervarix Characteristic Gardasil Cervarix Manufacturer Merck Frosst Canada Ltd. GlaxoSmithKline Inc. Type Prophylactic vaccine Prophylactic vaccine consisting of virus-like consisting of virus-like particles containing L1 particles containing L1 capsid proteins capsid proteins Antigens Quadrivalent vaccine: Bivalent vaccine: HPV types 6 HPV types (20 [micro]g/dose), 16 (20 [micro]g/dose) and 11 (40 [micro]g/dose), 18 (20 [micro]g/dose) 16 (40 [micro]g/dose) and 18 (20 [micro]g/dose) Antigen Yeast Baculovirus expression system Adjuvant Alum: ASO4: 225 [micro]g aluminum 500 [micro]g aluminum hydroxyphosphate sulfate hydroxide and 50 [micro]g 3-deacylated monophosphoryl lipid A Dose and 0.5 mL intramuscular 0.5 mL intramuscular schedule injection at 0, 2 and injection at 0, 1 and 6 months 6 months Availability Approved for sale Not yet available in Canada

  10. Table 2: Immune response and disease outcomes* for the HPV vaccines Gardasil and Ceravix Variable Gardasil Cervarix Published trial * Phase 2 and 3 * Phase 2 and 3 results trials (21-27) trials (28-31) Sample size * 20 583 (27) * 18 644 (31) Maximum duration of * 5 years * 5.5 years follow-up (phase 2) (23) (phase 2) (30) * 3 years * 1.25 (phase 3) (25) (phase 3) (31) Immune response 1 * Over 99% * Over 99% month after seroconversion seroconversion completion of vaccine series * Antibody titres 11 * Antibody titres 107 times (HPV type 6), times (HPV type 16) 7 times (HPV type and 82 times (HPV 11), 105 times (HPV type 18) higher type 16) and 19 than titres times (HPV type 18) following natural higher than titres infection (28) following natural HPV infection (22) Duration of immune * 96% seropositive to * 100% seropositive to response HPV types 6, 11 and HPV types 16 and 18 16 at 24 months at 51-53 months29 * 68% seropositive to HPV type 18 at 24 months (25) Persistent * Vaccine efficacy * Vaccine efficacy infection ([dagger]) 93.5% (95% CI 80.4% (95% CI from HPV types 16 83%-98%) (23) 70%-87%) (31) and 18 Cervical * Vaccine efficacy * Vaccine efficacy intraepithelial 98% (95% CI 90.4% (95% CI neoplasia (grade 2 93%-100%) (27) 53%-99%) (31) or higher) related to HPV types 16 and 18 Vaginal and vulvar * Vaccine efficacy * No data intraepithelial 97% (95% CI neoplasia (grade 2 79%-100%) (26) or higher) related to HPV types 16 and 18 Persistent * No data * Vaccine efficacy infection ([dagger]) 59.9% (95% CI of HPV type 45 3%-85%) (31) Persistent * No data * Vaccine efficacy infection ([dagger]) 36.1% (95% CI of HPV type 31 0.5%-60%) (31) Protection from * Vaccine efficacy * No data genital warts 96% (95% CI 86%-99%) (24)

  11. Video http://www.youtube.com/watch?v=6YKwPfFYR6chttp://www.becervixsavvy.co.uk/index.html

  12. Works Cited • Gale Encyclopedia of Cancer # 2 • Gale cengage Learning http://findgalegroup.com/ips/retrieve.do?cententSet=IAC-documents Fred Hutchinson Cancer Research Center http://fhcrc.org/reseach/disease/cervical_cancer/iindex.html Cervical Cancer: information at gargasil.com • National Cancer Institute • http://www.cancer.gov/cancertopics/types/cervical • National Cervical Cancer Coalition • http://www.nccc-online.org/ • American Cancer Society • http://www.cancer.org/docroot/CRI/content/CRI_2_4_1X_What_is_cervical_cancer_8.asp

  13. Pictures • http://keetsa.com/blog/eco-friendly/vegan-condoms-by-glyde/ • www.dailymail.co.uk • www.britannica.com

More Related